awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34229317-9A14837F-48CA-46CE-8736-C68133CF4DCE
Q34229317-9A14837F-48CA-46CE-8736-C68133CF4DCE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34229317-9A14837F-48CA-46CE-8736-C68133CF4DCE
Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
P2860
Q34229317-9A14837F-48CA-46CE-8736-C68133CF4DCE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34229317-9A14837F-48CA-46CE-8736-C68133CF4DCE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6d1fe72925d0ce9d4374123cbace10064a6510b6
P2860
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer